The cataractogenic effect of statins was hypothesized when a dose-dependent relationship was found in dogs. 9 The association between statins and cataract development in humans has been
investigated, but the findings are inconclusive. While some studies have suggested a decreased risk, [10] [11] [12] others found no risk differences [13] [14] [15] [16] and others an increased risk of cataracts among statin users. [17] [18] [19] [20] [21] Cataracts are responsible for one-third of all blindness cases and represent one-fifth of visual impairment worldwide. 22, 23 A cataract is defined as a degradation of the optical quality of the crystalline lens, which affects visual acuity, and can occur in both eyes. 24 Aging, cardiovascular and metabolic diseases, ophthalmic comorbidities, trauma, smoking, ultraviolet-B light, corticosteroids, and antidepressants are known risk factors. [24] [25] [26] Two meta-analyses including both randomized clinical trials (RCTs) and observational studies did not find consistent evidence demonstrating an increased risk of cataract development in association with the use of statins. 27, 28 However, one important limitation of these metaanalyses was the exclusion of a number of observational studies, some of which reporting increased risks. 11, 12, 18, 20, [29] [30] [31] [32] Although observational studies can be susceptible to selection bias when used to assess the intended effects of drugs, they are suitable for the study of rare, unpredictable, and long-term adverse effects of drugs. 33, 34 Moreover, the frequency of harmful effects experienced in clinical practice may be better reflected by noninterventional data, which has also supported a considerable number of drug label changes due to safety issues. [35] [36] [37] [38] The appropriate assessment of the eventual cataractogenic effect of statins based on experimental evidence would require a thorough review of the study registries of all RCTs ever conducted.
Besides the difficulties in accessing such data, none of the RCTs included in the already published meta-analyses considered the occurrence of cataract as a prespecified primary or secondary endpoint. 28, 39 Consequently, investigators could not have been aware of the eventual ocular iatrogenics caused by statins, which might have impaired an active and correct record of such events. 39 The continuous study of adverse effects of statins is important because they may unnecessarily prompt dose reduction or discontinuation of an essential medication. 8 Since statins are widely prescribed medicines and cataracts are a major health problem, it is important, from a public health perspective, to evaluate the consistency of the results from observational studies. Therefore, this systematic review and meta-analysis aims to evaluate whether the use of statins increases the risk of cataracts in the general population, when compared with the nonuse, by exclusively including data from published observational studies.
| ME THODS
This systematic review and meta-analysis was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. 40 PRISMA Checklist is presented at Table S1 .
| Bibliographic search
PubMed, EMBASE, and Cochrane Library were searched from its inception until July, 2018, in order to identify relevant studies evaluating the risk for cataract associated with statins. MeSH and Emtree terms, the MedDRA dictionary, v20.1., and the International Nonproprietary Names of statins were used in the search equations [41] [42] [43] Bibliographic references list of all relevant studies were hand searched. Search strategy is available in Table   S2 .
| Inclusion criteria, study selection, and quality assessment
Two independent reviewers screened the titles and abstracts of all retrieved citations (CA and DM) to identify relevant publications.
Full texts were retrieved for relevant citations. Discrepancies were resolved by majority decision involving a third investigator (FBM).
Studies with the following characteristics verified criteria for inclu- Only peer-reviewed full articles written in English were considered.
Studies' methodological quality was assessed through Newcastle-Ottawa scale, which considers the following characteristics: selection of the study groups; comparability of the groups;
and ascertainment of either the exposure (for case-control studies)
or outcome of interest (for cohort studies). 44 A maximum of one point for each item within the "Selection" and "Exposure/Outcome" categories could be awarded. For "Comparability" category, a maximum of two points could be awarded. The summary score equals the number of points earned by each study, totaling a maximum of 9 (maximum of 8 points for cross-sectional). 44 An adapted form of the Newcastle-Ottawa scale was used to assess cross-sectional studies. 45 Studies scoring ≥7 points were considered to be of good quality, those scoring <7 and ≥5 points were of moderate quality, and those scoring <5 points were considered to have poor quality. 45 Two independent reviewers assessed the methodological quality of the studies (CA and DM). A third investigator (FBM) helped resolving discrepancies by majority decision.
| Data extraction and outcome assessed
The following data were retrieved from studies: design, follow-up, participants' demographics, cataracts' risk factors, treatments, and estimated effect measures. The selected outcome measure of this meta-analysis was the risk of cataracts. Events included in the MedDRA Preferred Term "Cataract," "Cataract subcapsular," "Cataract nuclear," "Cataract cortical," "Cataract congenital," and "Lenticular opacities" were considered to define the outcome. 41 
| Statistical analysis
The meta-analyses were conducted based on the DerSimonian and
Laird random-effects model, which was used to pool ORs with their 
95% confidence intervals (CIs

| RE SULTS
The studies flow summary is described in Figure 1 . 
| Studies characteristics
Characteristics of the studies are described in Table S3 . Studies frequently reported data on smoking, diabetes mellitus, cardiovascular diseases, hypertension, and steroids usage, with a few describing the proportion of patients using SSRIs. Only three studies reported data on ophthalmic diseases. The proportion of patients with an additional risk factor for cataracts varied significantly between the studies. One study included only diabetic patients, most of them being hypertensive (>90%). 50 Studies' methodological quality is described in Table S4 .
Ten studies were considered to have good methodological quality, eight moderate quality, and three poor quality.
| Risk of developing cataracts
Treatment with statins was associated with an increased risk for cat- 1.09 (95% CI: 0.52-2.27), P = 0.825, I 2 = 89.2% ( Figure S1 ; Table 2 ).
Results suggest patients aged ≥65 years taking statins are at an increased risk for cataracts [OR: 1.13 (95% CI: 1.03-1.25); P = 0.013; Figure S2 ; Table 2 ). The meta-analysis of studies with a follow-up length ≥5 years also estimated an increased risk [OR: 1.21
(1.12-1.31); P < 0.001; I 2 = 76.0%] ( Figure S3 ; Table 2 ). The metaanalysis of studies with good methodological quality estimated an increased risk [OR: 1.17 (1.07-1.29); P = 0.001; I 2 = 93.5%], but not for those assessed as having exclusively fair or poor quality ( Figure   S4 ; Table 2 ). The initial risk estimate did not significantly change after excluding the three studies with poorer methodological quality from the analysis [OR: 1.11 (95% CI: 1.02-1.21); P = 0.020; I 2 = 97.9%].
When the results were stratified according to the outcome, the risk only remained increased among studies evaluating "cataract surgery" [OR: 1.16 (95% CI: 1.06-1.27; P = 0.001; I 2 = 94.4%; Figure S5 ; Table 2 ).The "one-study removed" analysis indicates that the overall risk estimate did not significantly change when any study was removed ( Figure S6 ). According to the meta-regression estimates, the risk of cataracts did not significantly vary according to studies' different proportions of patients diagnosed with hypertension, cardiovascular disease, smoking, or use of steroids or SSRIs (Table 3 ).
An inverse relationship between the risk of cataracts development and the proportion of diabetic patients in the studies was identified (Table 3) .
No publication bias was detected according Egger's asymmetry test (coefficient: −0.2765578; standard error: 1.970302; P = 0.890).
Subjective evaluation of publication bias was based on the visual inspection of the funnel plot, and no significant evidence of publication bias was identified ( Figure S7 ).
| D ISCUSS I ON
Meta-analysis allows obtaining a single estimate of the effect of interest from the results observed in each of several studies. 55 Publication of systematic reviews and meta-analyses has growing over the years, most of them designed to assess efficacy endpoints and integrating data from RCTs. 56, 57 Meta-analysis can also be an useful tool when it is conducted to assess drugs' safety. 36, 58, 59 The cumulative meta-analysis assessing how risk estimates perform over time may eventually support a timelier implementation of risk minimization measures. 36 Additionally, the drugs' safety assessment may be strengthened by exploring between-studies heterogeneity through subgroup meta-analyses and meta-regression. 60 The antioxidant and anti-inflammatory effects of statins were purposed as the reason for an eventual beneficial effect on cataract risk reduction, since oxidative stress and inflammation are linked with nuclear cataract development. 14 A statistically significant increased risk of cataracts due to statins was estimated in this meta-analysis, but the results are associated with significant between-studies heterogeneity. From a conservative point of view, it is recommended that systematic reviews 29 Prospective cohort study Twenty-nine patients with hypercholesterolemia were treated with simvastatin and followed over 2 y at half-year intervals. An age-and sex-matched group of patients were followed over a half year. Lenses were inspected for nuclear and cortical opacities, water clefts and vacuoles. 30 Retrospective cohort study Participants of The Age-Related Eye Diseases Study 2 (AREDS2), with bilaterally phakic at baseline and had cortical and posterior subcapsular (PSC) lens opacities.
TA B L E 1 Characteristics of the included studies
Study
Study design Population
Studied interventions
Cataract surgery was used as surrogate endpoint. Statin use was self-reported at baseline, and users were matched with nonusers using the propensity score approach. For cohort studies, data reported are related with the cases of cataract identified in patients exposed to statins; for case-control studies, data are related with the cases of patients who suffered a cataract/ cataract surgery and had been exposed to statins.
b n for proportion of days covered with statins ≥75%.
TA B L E 1 (Continued) A statistically significant increased risk for cataracts was identified among the studies with better methodological quality, though all the risk estimates were associated with significant between-studies heterogeneity.
Again, the definition of cataract as an endpoint was not similar between the studies. Most studies defined cases/endpoint using administrative database codes. However, identifying cataracts by retrospectively reviewing diagnosis codes may not provide detailed information regarding the visual impairment caused by the condition. 18 As an outcome in the observational studies, cataract was defined as an administrative code indicating surgery and/or a clinical diagnosis by a physician. Among other principles, referral for cataract surgery is based on a significant decrease in visual acuity which can impair daily tasks. 24 The sensitivity analysis demonstrated that, among the studies exclusively using cataract surgery as the outcome, the initially identified overall increased risk remains statistically significant. However, neither surgery nor clinical diagnosis used as outcomes ensures a comparable decision-making process allowing ascertaining the severity of the condition. 19, 20, 24 Moreover, clinical practice may differ among countries and regions, bringing additional difficulties when comparing the studies.
Few of the included studies evaluated the effect of statins in TA B L E 3 Meta-regressions' slope estimate, the respective standard error (SE), P value, and Adjusted-R treatment with lipid-lowering medications, is difficult to ascertain due to the uncertainty of the findings.
None of the risk factors evaluated in the meta-regression influenced the overall risk estimate, except diabetes mellitus, which was found to have an inverse relationship, contradicting published evidence. 24 Hypertension, diabetes mellitus, smoking, and corticosteroids are simultaneously risk factors for cataracts and for cardiovascular disease. 4 Nevertheless, the possibility of such bias has been present in this analysis cannot be definitely ruled out, particularly if the epidemiology techniques for matching were not the most adequate. 73 Moreover, most of the studies included in this meta-analysis reported different baseline proportions of patients with risk factors for cataracts and, some of them, did not report those proportions at all, which can reduce the robustness of the sensitivity analysis.
Despite including additional observational studies, the risk estimates of this meta-analysis are similar to those presented by the work of Yu and colleagues (2017) for the noninterventional data. 28 Additionally, these authors conducted several sensitivity analyses, but the prespecified variables did not completely explain the observed heterogeneity. A protective effect of statins in preventing cataracts found by Kostis and Dobrzynski (2013) seems, however, unlikely.
27
The findings of this systematic review and meta-analysis, although statistically significant risks have been estimated, present low values of OR, high heterogeneity, and elevated methodological variability among studies, which makes difficult to support a cataractogenic effect of statins. Therefore, since statins are effective in reducing cardiovascular disease, in the light of the current scientific evidence, no additional concerns should be present when using these medicines.
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